In in vivo experiments, we found that using AhR inhibitor CH223191 alone showed minimal effect upon limiting tumor growth while using CH223191 could largely reduce tumor growth under cisplatin, RT, or diABZI treatment; consistently, we also detected that CH223191 increased STING protein level and activation in tumor lysates as well as boosted intratumoral IFN-β levels (Fig. 4M-P and Supplementary Fig. 4N–Q). Here, AHR is linked to neoplasm.